Tumores Gastrintestinais
Estudo com base de dados nacional de 5.055 pacientes | Desfechos oncológicos e de curto prazo da cirurgia de extração de espécime via orifício natural (natural orifice specimen extraction surgery – NOSES) para câncer colorretal na China.
19 Jun, 2022 | 15:23hComunicado de imprensa: Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer – Science China Press
Diretriz ASGE sobre o rastreamento de câncer pancreático em indivíduos com suscetibilidade genética.
19 Jun, 2022 | 14:14hComentário: New guidelines for pancreatic cancer screening – Beth Israel Deaconess Medical Center
Comentário no Twitter
Sawhney et al share "ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations." https://t.co/P6OtmhXr2D pic.twitter.com/vDHWfKCAiN
— GIE (@GIE_Journal) May 26, 2022
Causas do câncer hepático estão mudando ao redor do mundo: algumas ganham força, outras perdem.
19 Jun, 2022 | 13:17hComunicado de imprensa: Causes of Liver Cancer are Changing Around the World: Some Up, Some Down – UC San Diego Health
Estudo original: Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer – Cell Metabolism (link para o resumo – $ para o texto completo)
Estudo randomizado | Tremelimumabe com durvalumabe em carcinoma hepatocelular irressecável.
16 Jun, 2022 | 12:01hTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence
Comentário no Twitter
Durvalumab plus a single dose of tremelimumab increased overall survival by just over 2.5 months in patients with unresectable hepatocellular carcinoma who had not received previous systemic therapy. Read more about the HIMALAYA trial by @GABOUALFA et al.: https://t.co/8d2qp54OLt pic.twitter.com/AA1RlSEP2a
— NEJM Evidence (@NEJMEvidence) June 6, 2022
Estudo randomizado fase 2 | FOLFOXIRI (ácido folínico, 5-fluorouracila, oxaliplatina e irinotecano) antecipada com bevacizumabe com ou sem atezolizumabe no tratamento de pacientes com câncer colorretal metastático.
16 Jun, 2022 | 11:58hUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
In phase II AtezoTRIBE study of the addition of atezolizumab to first-line FOLFOXIRI + bevacizumab improved PFS in pts with pMMR/MSS mCRC (median 13.1 vs 11.5 months; adjusted HR 0.70, 80% CI 0.57–0.87; P = 0.018): https://t.co/0dkRxjvjsx #ImmunoOnc #CRCSM
— NatureRevClinOncol (@NatRevClinOncol) May 31, 2022
Revisão sistemática | Testes para sangue oculto nas fezes à base de guáiaco vs. testes imunoquímicos para rastreamento de câncer colorretal em indivíduos com risco médio.
14 Jun, 2022 | 13:48h
Comentário no Twitter
💩 Which faecal blood test is more accurate in detecting #bowelcancer and large polyps in population screening? https://t.co/U2mLfk7ARo This systematic review looks at the evidence from 63 studies including almost 4 million individuals. @CochranePH @CCGlobalAgeing @CochraneCRC pic.twitter.com/xQeeADgHql
— The Cochrane Library (@CochraneLibrary) June 7, 2022
#ASCO22 – Estudo randomizado | Fluorouracil, leucovorina, oxaliplatina e irinotecano com panitumumabe vs. fluorouracil, leucovorina e oxaliplatina com panitumumabe para pacientes com câncer colorretal metastático tipo RAS/BRAF agressivo.
14 Jun, 2022 | 12:47h#ADA2022 – Estudo de coorte retrospectiva | Associação entre cirurgia bariátrica e risco de câncer e mortalidade em adultos com obesidade.
13 Jun, 2022 | 14:58hAssociation of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (gratuito por tempo limitado)
Editorial: Bariatric Surgery and Cancer Risk – JAMA (gratuito por tempo limitado)
Comunicado de imprensa: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic
Comentários no Twitter
In this study, among adults with #obesity, #bariatricsurgery compared with no surgery was associated with a significantly lower incidence of obesity-associated #cancer and cancer-related mortality. https://t.co/x2gz3RUdra
— JAMA (@JAMA_current) June 3, 2022
Retrospective cohort presented at the @AmDiabetesAssn: incidence rate of 3.0 events vs 4.6 events per 1,000 person-years, resp, & a 32% reduced risk for developing obesity-related cancer following weight loss via surgery. @ClevelandClinic
https://t.co/6jLDmhgJbR @JAMA_current
— Karl Nadolsky (@DrKarlNadolsky) June 4, 2022
#ASCO2022 – Estudo randomizado | Análise do DNA circulante de tumor como orientação para terapia adjuvante no câncer de cólon estágio II.
13 Jun, 2022 | 14:56hCirculating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: DNA shed from colon cancers into bloodstream successfully guides chemotherapy after surgery – Helps clarify the benefit of chemotherapy in stage II cancers – Johns Hopkins Medicine
Comentário: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network
Comentário no Twitter
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 pic.twitter.com/gvHMnGWbyE
— NEJM (@NEJM) June 4, 2022
#ASCO22 – Estudo de braço único fase 2 | Bloqueio PD-1 no câncer retal localmente avançado com deficiência do reparo de incompatibilidade.
13 Jun, 2022 | 14:39hPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)